Clinical Trials | 10707: Phase 2 Trial of CBX-12 for Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

The University of Virginia Comprehensive Cancer Center seeks adults ages 18 and over with Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer. The purpose of this study is to test the good and bad effects of the drug called CBX-12. CBX-12 could shrink your cancer, but it could also cause side effects. The study doctors hope to learn if CBX-12 will shrink tumors by at least 30% compared to its present size in your type of cancer. CBX-12 is considered an investigational drug because it is not approved by the FDA for treatment of your disease. The study involves receiving the investigational drug, as well as coming in for study visits, which include exams, laboratory tests, and procedures such as having your blood drawn, imaging, and talking to the study doctor. If you choose to take part and are deemed eligible for participation, you will get the study drug, CBX-12, once every 21 days by infusion over 60 minutes (±15 minutes). You will continue treatment unless your disease gets worse, or the side effects become too severe. After you finish your study treatment, your doctor will continue to monitor you for side effects for 30 days. After that, they will continue to follow your condition every 3 months for 12 months via phone call or office visit. You and/or your insurance plan will need to pay for the costs of medical care you get as part of the study, just as you would if you were getting the usual care for your cancer. You and/or your insurance provider will not have to pay for the study drug, CBX-12, or any exams, tests, and procedures done for research purposes only or that are covered by the study. Additional information can be found here: https://www.clinicaltrials.gov/study/NCT06730100 [email protected]